Insights for cannabinoid product developers

Article

Why bioavailability matters in cannabinoid formulations

Developing a successful cannabinoid product is about more than selecting a high-quality active ingredient. The real challenge is ensuring that the active compound is effectively absorbed by the body. Orally administered CBD has been shown to have low absolute bioavailability, around 6% in published pharmacokinetic literature.